![Chemical structure of 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one, CAS 320-67-2](https://api.angenesci.com/structure/1184/320-67-2.png)
No data
No data
No data
| CAS Number | 320-67-2 |
| Catalog Number | AG003824(AGN-PC-0R7ECF) |
| Chemical Name | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one |
| EC Number | 206-280-2 |
| IUPAC Name | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one |
| InChI | InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1 |
| InChI Key | NMUSYJAQQFHJEW-KVTDHHQDSA-N |
| MDL Number | MFCD00006539 |
| Molecular Formula | C8H12N4O5 |
| Molecular Weight | 244.2047 |
| NSC Number | 758186 |
| SMILES | OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc(nc1=O)N |
| UNII | M801H13NRU |
| Synonyms | 5 Azacytidine,
5-Azacytidine,
Azacitidine,
Azacytidine,
NSC 102816,
NSC-102816,
NSC102816,
Vidaza,
5-azacytidine,
Azacitidine,
320-67-2,
Ladakamycin,
Azacytidine,
Vidaza,
Mylosar,
Azacitidina,
Azacitidinum,
5-azacitidine,
Azacitidinum [INN-Latin],
5-AZAC,
Azacitidina [INN-Spanish],
5 AZC,
NSC-102816,
U-18496,
CCRIS 60,
UNII-M801H13NRU,
NSC102816,
5AzaC,
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one,
Antibiotic U 18496,
HSDB 6879,
WR-183027,
5-AZCR,
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one,
EINECS 206-280-2,
BRN 0620461,
5-AC,
CHEBI:2038,
M801H13NRU,
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one,
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one,
NSC 102816,
MFCD00006539,
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one,
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one,
4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one,
NCGC00090851-04,
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one,
NCI-C01569,
5-Azacytidine, 99%,
1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-,
DSSTox_CID_116,
U 18496,
DSSTox_RID_75378,
DSSTox_GSID_20116,
wr 183027,
mylo sar,
Azacitidine [USAN:INN],
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one,
SMR000857239,
Vidaza (TN),
5-aza-CR,
SR-01000075662,
Azacitidine (JAN/USAN/INN),
Azacitidine [USAN:INN:BAN],
NS-17,
1-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-amino-1,3,5-tri azin-2-one,
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one,
CAS-320-67-2,
Azacitidine(Vidaza),
Azacitidine (Vidaza),
Antibiotic U18496,
U18496,
PubChem14167,
Spectrum_001262,
Spectrum2_000786,
Spectrum3_001509,
Spectrum4_000922,
Spectrum5_001166,
MolMap_000062,
A 2385,
AC1L1T1Y,
SCHEMBL3741,
CHEMBL1489,
Lopac0_000035,
BSPBio_003157,
KBioGR_001444,
KBioGR_002556,
KBioSS_001742,
KBioSS_002565,
KSC222S1T,
MLS001333121,
MLS001333122,
MLS002153249,
MLS002548894,
DivK1c_000125,
SPECTRUM1502111,
SPBio_000892,
EOS113,
GTPL6796,
Jsp005945,
DTXSID9020116,
BCBcMAP01_000083,
CTK1C2919,
HMS500G07,
KBio1_000125,
KBio2_001742,
KBio2_002556,
KBio2_004310,
KBio2_005124,
KBio2_006878,
KBio2_007692,
KBio3_002657,
KBio3_003034,
NMUSYJAQQFHJEW-KVTDHHQDSA-,
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one,
pyrimidine antimetabolite: inhibits nucleic acid replication,
cMAP_000082,
NINDS_000125,
NMUSYJAQQFHJEW-KVTDHHQDSA-N,
HMS1921J22,
HMS2092D08,
HMS2231F15,
HMS3259D19,
HMS3260G11,
Pharmakon1600-01502111,
ZINC3861768,
5-Azacytidine, >=98% (HPLC),
Tox21_111032,
Tox21_302985,
Tox21_500035,
ABP001093,
ANW-27256,
BDBM50424715,
CCG-39046,
EBD145507,
NSC758186,
s1782,
SBB066305,
AKOS015896938,
Tox21_111032_1,
AM83944,
API0003444,
CS-1287,
DB00928,
LP00035,
LS-1189,
MCULE-8318770472,
NC00672,
NSC-758186,
NSC103-627,
RP28647,
RTR-013523,
SB18981,
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz,
IDI1_000125,
5-azacytidine;Mylosar;Ladakamycin;Vidaza,
NCGC00090851-01,
NCGC00090851-02,
NCGC00090851-03,
NCGC00090851-05,
NCGC00090851-06,
NCGC00090851-07,
NCGC00090851-08,
NCGC00090851-10,
NCGC00178234-01,
NCGC00256541-01,
NCGC00260720-01,
AS-13697,
CC-21195,
CPD000857239,
HY-10586,
SAM002264595,
SC-09078,
SRI-10756_10,
SRI-10756_12,
ST056940,
WR183027,
AB2000290,
AX8008347,
DB-006955,
SL-000003,
TR-013523,
A5777,
EU-0100035,
FT-0081170,
FT-0601307,
ST24044344,
TL80073599,
C11262,
D03021,
J10124,
33795-EP2275420A1,
33795-EP2295055A2,
33795-EP2295416A2,
33795-EP2298748A2,
33795-EP2298764A1,
33795-EP2298765A1,
33795-EP2305642A2,
33795-EP2311453A1,
33795-EP2311840A1,
124679-EP2270008A1,
124679-EP2292617A1,
124679-EP2295426A1,
124679-EP2295427A1,
320A672,
C-14788,
J-700085,
SR-01000075662-1,
SR-01000075662-3,
SR-01000075662-7,
U-18,496,
BRD-K03406345-001-02-1,
BRD-K03406345-001-27-8,
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-,
Z1522566611,
4-Amino-1-(bet.-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one,
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI),
Azacitidine, United States Pharmacopeia (USP) Reference Standard,
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin,
Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material,
4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-,
5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma,
5AE,
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1,
5 Azacytidine,
Ledakamycin,
Azacytidine, 5-,
FAZARABINE,
Vidaz (TN),
Azacytidine/5-Azacytidine,
D09FAZ,
C8H12N4O5,
5-Fluoro-2-nitrobenzoicacid,
Pharmion Brand of Azacitidine,
5-fluoro-2-nitro-benzoic Acid,
CID9444,
5-Azacytidine, 99% - 1G 1g,
Amino-beta-D-ribofuranosyltriazinone,
C8-H12-N4-O5,
ACN-038132,
CS-O-10043,
A1907,
A10105,
D001374,
4-Amino-1-?-D-ribofuranosyl-1,3,5-triazin-2(1H)-one,
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine,
S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI),
1,3,5-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl-,
320-98-9,
931-86-2,
one,
|
| Complexity | 384 |
| Compound Is Canonicalized | Yes |
| Covalently-Bonded Unit Count | 1 |
| Defined Atom Stereocenter Count | 4 |
| Defined Bond Stereocenter Count | 0 |
| Exact Mass | 244.081g/mol |
| Formal Charge | 0 |
| Heavy Atom Count | 17 |
| Hydrogen Bond Acceptor Count | 5 |
| Hydrogen Bond Donor Count | 4 |
| Isotope Atom Count | 0 |
| Molecular Weight | 244.207g/mol |
| Monoisotopic Mass | 244.081g/mol |
| Rotatable Bond Count | 2 |
| Topological Polar Surface Area | 141A^2 |
| Undefined Atom Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| XLogP3 | -2.2 |
| Symbol: | |
| Hazard Class | \N |
| Hazard statements | H302-H315-H319-H335-H350-H360 |
| Packing Group | \N |
| Precautionary statements | P261-P305+P351+P338 |
| UN Code | \N |
| Chemical Name: | Batch Number: | |
| Chemical Structure: | CAS Registry No: | |
| Product ID: | ||
| Manufacture Date: | ||
| Storage Temperature: | ||
| Formula: | ||
| Molecular Weight: | ||
| Quantity: |
| Test: | Result: |

